Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110589

Characterization of Serum Resistance of Neisseria gonorrhoeae that Disseminate: ROLES OF BLOCKING ANTIBODY AND GONOCOCCAL OUTER MEMBRANE PROTEINS

Peter A. Rice and Dennis L. Kasper

The Maxwell Finland Laboratory for Infectious Diseases, Boston City Hospital, Boston University School of Medicine, Boston, Massachusetts 02118

Channing Laboratory, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02115

Find articles by Rice, P. in: PubMed | Google Scholar

The Maxwell Finland Laboratory for Infectious Diseases, Boston City Hospital, Boston University School of Medicine, Boston, Massachusetts 02118

Channing Laboratory, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02115

Find articles by Kasper, D. in: PubMed | Google Scholar

Published July 1, 1982 - More info

Published in Volume 70, Issue 1 on July 1, 1982
J Clin Invest. 1982;70(1):157–167. https://doi.org/10.1172/JCI110589.
© 1982 The American Society for Clinical Investigation
Published July 1, 1982 - Version history
View PDF
Abstract

Neisseria gonorrhoeae isolated from patients with disseminated infection (DGI) often resist complement (C′)-dependent killing by normal human serum (NHS) and less commonly by convalescent DGI serum. 7 of 10 NHS specimens completely inhibited killing of serum-resistant (serr) gonococci by convalescent or immune DGI serum. Immunoglobulin G (IgG) purified from NHS was shown to be the blocking agent. In addition, IgM (plus C′) purified from NHS was shown to be fivefold more effective (wt/wt) in killing serum-sensitive (sers) gonococci than equivalent amounts of IgM tested in the presence of IgG (whole serum). Although inhibition of NHS killing of sers gonococci required a 640% excess of IgG, only a 40% excess was required to block immune serum killing of serr gonococci. F(ab′)2 prepared from IgG also blocked killing of serr gonococci by immune serum indicating antigenic specificity of blocking IgG.

IgG immunoconcentrated against outer membrane protein (OMP) derived from serr gonococci showed 40-fold increased blocking activity over normal IgG (wt/wt) and lacked antibody activity directed against gonococcal lipopolysaccharide by ELISA. Using direct immunoabsorption of IgG with purified gonococcal OMP; serr-OMP was found sixfold more effective than sers-OMP in neutralizing the blocking of immune serum killing of serr gonococci, and 10-fold more effective in systems that used excess blocking IgG, NHS, and sers gonococci. Blocking IgG preabsorbed with whole serr gonococci lost 75% of its ability to block immune serum killing compared with no loss in this system using a similar absorption with sers gonococci. IgG purified from NHS contained fivefold higher titers of antibody against serr-OMP than sers-OMP by ELISA.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 157
page 157
icon of scanned page 158
page 158
icon of scanned page 159
page 159
icon of scanned page 160
page 160
icon of scanned page 161
page 161
icon of scanned page 162
page 162
icon of scanned page 163
page 163
icon of scanned page 164
page 164
icon of scanned page 165
page 165
icon of scanned page 166
page 166
icon of scanned page 167
page 167
Version history
  • Version 1 (July 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts